(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Civilian toll mounts in Iran as war presses on - 2Fiber is something most people could use more of. But experts advise caution with 'fibermaxxing'
- 3The most effective method to Shake Hands During a Pandemic: Wellbeing Tips and Behavior
- 4Select Your Cherished Fish
- 5Hundreds of Gazans evacuated from Strip for medical treatment - COGAT
- 21 Incredibly Entertaining Contemplations To Observe Consistently
- More parents refusing vitamin K shots for newborns, study finds
- Manual for Financial plan Agreeable PC
- Rick Steves Prefers Paying A Bit Extra For This Delectable Food When Dining In Spain
- She just became the first wheelchair user to travel to space
- 5 Worldwide Road Food varieties You Should Attempt
- 'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- Scientists document a death from a meat allergy tied to certain ticks
- Israel and Lebanon's Hezbollah continue to trade attacks
